Drilldown: Medicines

None (2) · Bisoprolol (1) · Nebivolol (1) · Solifenacin (1)

Ajovy (1) · Bystolic (1) · Emgality (1) · Vesicare (1) · Zebeta (1)

Anti-CGRP ligand monoclonal antibody (2) · Beta Blocker (2) · Cardioselective (β1) (1) · Cardioselective (β1) + vasodilator (1) · [[:Category:Antimuscarinics|Antimuscarinic (M3-selective)]] (1) · [[:Category:Overactive_bladder_medications|Overactive bladder medication]] (1)

Highly β1-selective adrenergic antagonist. Greater selectivity than metoprolol or atenolol. (1) · Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) · Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) · The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1) · '"`UNIQ--vote-00000DFA-QINU`"' CYP3A4 substrate; QT-interval prolongation has been reported at higher doses. Like other antimuscarinics, contributes to cumulative anticholinergic burden in older adults'"`UNIQ--ref-00000DFB-QINU`"'. (1)

Preventive treatment of migraine in adults (episodic and chronic) (1) · Preventive treatment of migraine in adults; episodic cluster headache (1) · '"`UNIQ--vote-0000059D-QINU`"' (1) · '"`UNIQ--vote-00000636-QINU`"', '"`UNIQ--vote-00000637-QINU`"', '"`UNIQ--vote-00000638-QINU`"' (1) · '"`UNIQ--vote-00000DFC-QINU`"', '"`UNIQ--vote-00000DFD-QINU`"' (1)

2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration) (1) · 225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) · 5 mg daily (1) · 5 mg PO once daily; titrate to 10 mg after 2 weeks if needed (1) · Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1)

120 mg/mL prefilled syringe or autoinjector (1) · 2.5, 5, 10, 20 mg tabs (1) · 225 mg/1.5 mL prefilled syringe or autoinjector (1) · 5, 10 mg tablets (1) · 5, 10 mg tabs (1)

10 mg/d (5 mg if severe renal or moderate hepatic impairment, or strong CYP3A4 inhibitors) (1) · 20 mg/d (1) · 240 mg loading + 120 mg/month for migraine; 300 mg/month for cluster (1) · 40 mg/d (1) · 675 mg/quarter (1)

Oral (3) · Subcutaneous (2)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

24 h (2) · 24 hours (1) · Monthly dosing (1) · Monthly or quarterly dosing (1)

9–12 h (1) · ~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers) (1) · ~27 days (1) · ~31 days (1) · ~45-68 hours'"`UNIQ--ref-00000DFE-QINU`"' (1)

Not formally established (1) · Not formally established (high SC) (1) · ~12% (extensive metabolizers); ~96% (poor metabolizers) (1) · ~90% (low first-pass) (1) · ~90% (oral)'"`UNIQ--ref-00000DFF-QINU`"' (1)

Category C (2) · Limited data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited data; avoid (2)

Rx (2) · Rx-only in US (2) · [[USLegal:Prescription only|Rx-only]] in US (1)